Delivering more for human health and beyond

 

Medlab Clinical (ASX: MDC) is an Australian publicly listed biotechnology company with a global market opportunity. Our team of scientists, researchers and doctors are dedicated to building products that are scientifically optimised for a better life, specialising in oncology and enhanced drug delivery.

Medlab has a portfolio of novel cannabinoid-based assets enhanced by our leading drug delivery platform. Our lead drug candidate, NanaBis™, is an opioid alternative for cancer-induced pain management, with company-making potential and a global market opportunity. 

Core to our value proposition is NanoCelle®, our patented sub-micron drug delivery platform that vastly improves drug solubility issues and enables faster absorption and metabolism of active ingredients. NanoCelle® underpins our growth strategy by offering near-term partnering opportunities whilst enhancing our pharma portfolio. 

Investment Highlights

  • Patented NanoCelle® drug delivery platform with value creation optionality, enhancing our product portfolio whilst offering near term partnering opportunities
  • World-class Board, management and scientific consulting team with strong experience bringing novel therapeutics to market
  • Scientifically optimised portfolio of cannabinoid therapeutics addressing a global unmet need in oncology areas including pain management
  • Lead candidate NanaBis™ Phase I/II primary and secondary endpoints met in bone cancer patients, replicated in a real-world observational study. Stage III commencing in near-term with robust and clear drug pathway in US, EU and Australia
  • NanaBis™ proof of concept established and early revenue being generated via Special Access Scheme

 

 

 

 

Have an investor relationship question, you can book a meeting with our CEO, Dr Sean Hall

 

 

 

 

Schedule a meeting

Sign up for Investor Updates

 

Stay up-to-date with the latest investor news, presentations and videos from Medlab sent directly to your email address.

Subscribe

* indicates required

Latest Investor News

Small Caps interview of CEO Sean Hall

Small Caps interviews the CEO of Medlab, Sean Hall about the future of NanoCelle® drug delivery technology and pharmaceutical portfolio


2021-04-22

Medlab Clinical and microsoft mixed reality hololens 2

Medlab mixes reality with Microsoft

Read the three featured stories from Microsoft about Medlab's adoption of mixed reality solutions including HoloLens 2 head-mounted devices with Dynamics 365 Remote Assist, to help combat the pandemic by improving time to market and guaranteeing crucial business progression.


2021-04-14

NanaBis improvement in pain scores observational study

NanaBis demonstrates continued improvement in pain scores

The first cohort of Observational Study patients completing 12-month treatment with NanaBis™ demonstrated continued improvement in pain scores.


2021-04-12

Medlab Clinical to be granted European patent for NanoCelle drug delivery platform

Medlab to be granted European patent for NanoCelle® drug delivery platform

European Patent Office issues Notice of Intention to grant Medlab Clinical patent for NanoCelle® drug delivery platform


2021-04-07

Novartis Managing Director of Oncology (ANZ/NZ) appointed to board of Medlab Clinical

Novartis’ Managing Director of Oncology (ANZ/NZ) joins Medlab Clinical board

Medlab Clinical appoints Novartis' Managing Director of Oncology for Australia and New Zealand as Non-Executive Director.


2021-03-23

Medlab Clinical Raises Cash for phase 3 clinical trial and Leading Novartis Executive Joins Board

Medlab Clinical raises $15 million and Leading Executive Joins Board

Medlab Clinical successfully raised $15 million to help fund its upcoming Phase III clinical trial and has extended its board expertise with the appointment of leading pharmaceutical executive Mrs Cheryl Maley.


2021-03-19

Medlab Clinical equity injection

Medlab Clinical looks for $15 million equity injection

Medlab clinical looks to raise $15 million to fund its Phase III trial. Read more here.


2021-03-17

Medlab Clinical partners with Arrotex

Medlab Clinical partners with Arrotex

Medlab Clinical partners with Arrotex to accelerate NanoCBD availability in Australian pharmacies


2021-02-18

Medlab Clinical to confirm NanaBis’ potential as non-opioid pain treatment in phase three trials

Medlab to confirm NanaBis’ potential as non-opioid analgesic in phase III trial

Read the write up from Small Caps about Medlab's non-opioid pain treatment


2021-01-27

Ausbiz interview of CEO Sean Hall

Ausbiz interviews the CEO of Medlab, Sean Hall about the future of Medlab


2021-01-27

IND Acceptance Investor Update

NanaBis has been granted IND status by the US FDA, allowing Medlab to initiate its pivotal Phase III study at US sites


2021-01-19

Switzer Investor Day

4th Small and Micro-Cap Virtual Investor Day


2020-12-02

Ausbiz interview

Ausbiz interviews the CEO of Medlab, Sean Hall about the future of Medlab


2020-12-02

Nanabis Presentation

Nanabis Presentation

Learn more about NanaBis and the significant opportunity ahead


2020-09-01

StockPal Webinar

StockPal Webinar

In this part two of a four-part webinar recap, Sean Hall, Chief Executive Officer and Managing Director of Medlab (ASX:MDC) presented on the company’s latest announcements and updates while answering some questions during the Q&A session at the end.


2020-08-11